Skip to Main content Skip to Navigation
Journal articles

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.

Abstract : BACKGROUND: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk of cardiovascular mortality in this population. In contrast to patients with normal renal function, the benefits of modifying lipid levels on cardiovascular outcomes in patients with ESRD on haemodialysis have yet to be confirmed in large prospective randomised trials. A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA) will be the first large-scale international trial to assess the effects of statin therapy on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis. METHODS: More than 2,750 ESRD patients who have been receiving chronic haemodialysis treatment for at least 3 months have been randomised (1:1), irrespective of baseline lipid levels, to treatment with rosuvastatin 10 mg or placebo. The primary study endpoint is the time to a major cardiovascular event (first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). Secondary endpoints include all-cause mortality, major cardiovascular event-free survival time, time to cardiovascular death, time to non-cardiovascular death, cardiovascular interventions, tolerability of treatment and health economic costs per life-year saved. Study medication will be given until 620 subjects have experienced a major cardiovascular event. CONCLUSION: Our hypothesis is that results from AURORA will establish the clinical efficacy and tolerability of rosuvastatin in patients with ESRD receiving chronic haemodialysis and guide the optimal management of this expanding population.
Complete list of metadatas

Cited literature [48 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00090476
Contributor : Françoise Maylin <>
Submitted on : Thursday, August 31, 2006 - 2:32:42 PM
Last modification on : Friday, September 11, 2020 - 2:38:35 PM
Long-term archiving on: : Tuesday, September 18, 2012 - 4:53:37 PM

Identifiers

Collections

Citation

Bengt Fellström, Faiez Zannad, Roland Schmieder, Hallvard Holdaas, Alan Jardine, et al.. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.. Current Controlled Trials in Cardiovascular Medicine, BioMed Central, 2005, 6, pp.9. ⟨10.1186/1468-6708-6-9⟩. ⟨inserm-00090476⟩

Share

Metrics

Record views

286

Files downloads

496